Emerging Infectious Disease ISSN: 1080-6059

Antimicrobial Drug Resistance, Regulation, and Research¹

Joshua P. Metlay*†

, John H. Powers‡, Michael N. Dudley§, Keryn Christiansen¶, Roger G. Finch#**, and on behalf of the Second Colloquium of the International Forum on Antibiotic Resistance

Author affiliations: *VA Medical Center, Philadelphia, Pennsylvania, USA; †University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; ‡US Food and Drug Administration, Rockville, Maryland, USA; §Diversa Corporation, San Diego, California, USA; ¶Royal Perth Hospital, Perth, Western Australia, Australia; #Nottingham City Hospital, Nottingham, United Kingdom; **University of Nottingham, Nottingham, United Kingdom

Main Article

Figure 2

Figure 2. Defining the pharmacodynamic target for therapy. Adapted with permission from Blackwell Scientific (13).

Main Article

¹This article is based on presentations and discussions held at the Second Colloquium of the International Forum on Antibiotic Resistance (IFAR), held on September 13, 2003, in Chicago, Illinois, USA. IFAR is a multidisciplinary, international group concerned with evaluating current knowledge regarding antimicrobial drug resistance and the means for its control. This article represents the opinions of the participants at the second IFAR colloquium and not necessarily those of the institutions for whom they work.

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.